Clinical Evaluation of Using Intense Pulsed Light for Improving the Appearance of Striae Distensae

October 15, 2020 updated by: Venus Concept

Clinical Evaluation of Venus Versa SR Applicator Using Intense Pulsed Light on Skin Texture for Improving the Appearance of Striae Distensae

This trial is intended to evaluate the effect of IPL treatment on the Striae Distensae. The study hypothesis is that the SR580 applicator will improve the appearance of Striae Distensae by at least 1 point on the Global Aesthetic Improvement ScaleI (GAIS) at 3 months follow-up compared to baseline in at least 50% of the study population.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Study Design This is a multi-site, prospective, open labeled clinical trial with before-after study design. This study will include up to 8 visits at the clinic: initial screening/consultation, 5 treatments, visits in 2 week intervals, and 2 follow-up visits at 1 and 3 months after the last treatment visit.

Up to 60 healthy subjects age 24-65 with Striae Distensae will be enrolled.

Study duration:

Duration of subject's participation: Up to 5.5 months from enrollment to termination

Blinding Objective assessment of clinical improvement by global assessment scale will be achieved by sending before/after pictures (baseline/3months after last treatment) to 3 blinded reviewers at the end of the study.

Study Procedures Test Spots Up to 3 test spots will be performed in the selected treatment area to determine the optimal parameters / settings

Treatment visits Each subject will be enrolled and scheduled for 5 treatments at 2 week intervals and return for follow-up visits at one month and 3 months after the last treatment for evaluation of the treated areas. The duration of the entire treatment visit is approximately 60 minutes.

Treatment The treatment areas are divided into 2 treatment areas: abdomen or thighs. Apply a thin layer of IPL gel. Place the applicator in close contact, perpendicular to the skin with no pressure applied. Pressing the applicator will fire the IPL pulse.

Administer pulses throughout the treated area to ensure full coverage of the treated area with applicator overlap approximately 1/3 of the previously treated skin.

A single pass over the area is completed Remove the remnants of the IPL gel and dry thoroughly. Cold air or cold, wet but not frozen gauze pads may be placed on the treated area for post treatment cooling.

Typical responses to the treatment are mild erythema and edema.

Study Type

Interventional

Enrollment (Actual)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Beverly Hills, California, United States, 90211
        • Rosenberg Plastic Surgery

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

24 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Able to provide written Informed Consent;
  2. Healthy male or female, 24-65 years Fitzpatrick-Goldman skin type I-V;
  3. Having visible Striae Distensae to be treated (abdomen/thighs);
  4. Comply with the treatment/follow-up schedule and requirements;
  5. Women of child-bearing age are required to be using a reliable method of birth control

Exclusion Criteria:

  1. Fitzpatrick-Goldman skin type VI;
  2. Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after breastfeeding;
  3. Heavy smoker
  4. Unable or unlikely to refrain from tanning
  5. Use of photosensitive medication
  6. Use of oral isotretinoin within 3 months
  7. Any dermal/epidermal damage or disorder in treated area
  8. Prior treatment in treated area within 3 months
  9. Prior skin laser/light or another device treatment in treated area within 6 months
  10. Prior use of collagen, fat injections or other methods of skin augmentation in treated area within 12 months
  11. Prior use of Botox in treatment area within 6 months
  12. Prior ablative resurfacing procedure with laser in treatment area within 12 months
  13. Any other surgery in treated area within 9 months
  14. Participation in a study of another investigational device or drug as per the Investigator's discretion
  15. History of keloid or any other type of hypertrophic scar formation or poor wound healing in a previously injured skin area
  16. Showing symptoms of hormonal disorders (such as Melasma, Chloasma);
  17. Concurrent inflammatory skin conditions, open laceration or abrasion of any sort on area to be treated during the course of treatment
  18. Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study
  19. Multiple dysplastic nevi in area to be treated
  20. Having a bleeding disorder or taking anticoagulation medications
  21. History of immunosuppression/immune deficiency disorders
  22. Having any form of active cancer at the time of enrollment and during the course of the study or history of skin cancer
  23. Pigmented lesion in the treated area that appears cancerous
  24. Significant concurrent illness, such as uncontrolled diabetes
  25. Active infections in the treated area

28.Tattoo or permanent makeup at the treatment area. 29.Mentally incompetent, prisoner or evidence of active substance or alcohol abuse 30.Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Treatment Group
Group receiving treatment with Venus Versa IPL energy
The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Improvement in Striae Distensae Appearance
Time Frame: 90 days following last IPL treatment
Striae distensae appearance improvement by at least 1 point on the Global Aesthetic Improvement scale (GAIS) from photographs 3 months following the last treatment as determined by 3 blinded reviewers where 3 = Very Much Improved, 2 = Much Improved, 1 = Improved, 0 = No Change, -1 = Worse, -2 = Much Worse and -3 = Very Much Worse.
90 days following last IPL treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 13, 2015

Primary Completion (ACTUAL)

February 15, 2017

Study Completion (ACTUAL)

March 31, 2017

Study Registration Dates

First Submitted

May 8, 2015

First Submitted That Met QC Criteria

May 21, 2015

First Posted (ESTIMATE)

May 22, 2015

Study Record Updates

Last Update Posted (ACTUAL)

November 3, 2020

Last Update Submitted That Met QC Criteria

October 15, 2020

Last Verified

October 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CS0315

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Striae Distensae

Clinical Trials on Venus Versa

Subscribe